MAXCYTE INC. - COMMON STOCK

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

07 May 2025 15:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

10 Apr 2025 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

11 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

12 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

07 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

30 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

13 Jan 2025 02:05:00 By Nasdaq GlobeNewswire

MaxCyte Announces Retirement of Board Member Art Mandell

23 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

09 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

13 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

06 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

31 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Cynthia Collins to its Board of Directors

15 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

11 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

10 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

16 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

05 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

06 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

09 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

29 May 2024 07:05:00 By Nasdaq GlobeNewswire